These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36536364)

  • 1. Efficacy of eicosapentaenoic acid in inflammatory depression: study protocol for a match-mismatch trial.
    Suneson K; Ängeby F; Lindahl J; Söderberg G; Tjernberg J; Lindqvist D
    BMC Psychiatry; 2022 Dec; 22(1):801. PubMed ID: 36536364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-3 fatty acids for inflamed depression - A match/mismatch study.
    Suneson K; Söderberg Veibäck G; Lindahl J; Tjernberg J; Ståhl D; Ventorp S; Ängeby F; Lundblad K; Wolkowitz OM; Lindqvist D
    Brain Behav Immun; 2024 May; 118():192-201. PubMed ID: 38432599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.
    Rapaport MH; Nierenberg AA; Schettler PJ; Kinkead B; Cardoos A; Walker R; Mischoulon D
    Mol Psychiatry; 2016 Jan; 21(1):71-9. PubMed ID: 25802980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: Protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial.
    Wessa C; Janssens J; Coppens V; El Abdellati K; Vergaelen E; van den Ameele S; Baeken C; Zeeuws D; Milaneschi Y; Lamers F; Penninx B; Claes S; Morrens M; De Picker L
    Brain Behav Immun Health; 2024 Nov; 41():100871. PubMed ID: 39350954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
    Yang C; Bosker FJ; Li J; Schoevers RA
    BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial.
    Chang JP; Chang SS; Chen HT; Chien YC; Yang HT; Huang SY; Tseng PT; Chang CH; Galecki P; Su KP
    Brain Behav Immun; 2023 Aug; 112():125-131. PubMed ID: 37301235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
    Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC
    Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial.
    Mischoulon D; Dunlop BW; Kinkead B; Schettler PJ; Lamon-Fava S; Rakofsky JJ; Nierenberg AA; Clain AJ; Mletzko Crowe T; Wong A; Felger JC; Sangermano L; Ziegler TR; Cusin C; Fisher LB; Fava M; Rapaport MH
    J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 36005883
    [No Abstract]   [Full Text] [Related]  

  • 10. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
    Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
    Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mothers, Omega-3 and mental health study.
    Mozurkewich E; Chilimigras J; Klemens C; Keeton K; Allbaugh L; Hamilton S; Berman D; Vazquez D; Marcus S; Djuric Z; Vahratian A
    BMC Pregnancy Childbirth; 2011 Jun; 11():46. PubMed ID: 21696635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.
    Mocking RJ; Harmsen I; Assies J; Koeter MW; Ruhé HG; Schene AH
    Transl Psychiatry; 2016 Mar; 6(3):e756. PubMed ID: 26978738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.
    Jazayeri S; Tehrani-Doost M; Keshavarz SA; Hosseini M; Djazayery A; Amini H; Jalali M; Peet M
    Aust N Z J Psychiatry; 2008 Mar; 42(3):192-8. PubMed ID: 18247193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.
    Lucas M; Asselin G; Mérette C; Poulin MJ; Dodin S
    Am J Clin Nutr; 2009 Feb; 89(2):641-51. PubMed ID: 19116322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial.
    Carney RM; Freedland KE; Rubin EH; Rich MW; Steinmeyer BC; Harris WS
    JAMA; 2009 Oct; 302(15):1651-7. PubMed ID: 19843899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators.
    Lamon-Fava S; Liu M; Dunlop BW; Kinkead B; Schettler PJ; Felger JC; Ziegler TR; Fava M; Mischoulon D; Rapaport MH
    Neuropsychopharmacology; 2023 May; 48(6):929-935. PubMed ID: 36635595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder.
    Kavakbasi E; Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert KO; Clark SR; Fourrier C; Baune BT
    J Neurochem; 2024 Sep; 168(9):1817-1825. PubMed ID: 37635396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.
    Guu TW; Mischoulon D; Sarris J; Hibbeln J; McNamara RK; Hamazaki K; Freeman MP; Maes M; Matsuoka YJ; Belmaker RH; Jacka F; Pariante C; Berk M; Marx W; Su KP
    Psychother Psychosom; 2019; 88(5):263-273. PubMed ID: 31480057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal C-reactive protein blood levels as a specific biomarker of major depression and non-remission under antidepressants in schizophrenia.
    Fond G; Micoulaud-Franchi JA; Faugere M; Boyer L; Faget-Agius C; Lançon C; Richieri R; Cermolacce M
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Mar; 97():109800. PubMed ID: 31676465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Hellmann-Regen J; Clemens V; Grözinger M; Kornhuber J; Reif A; Prvulovic D; Goya-Maldonado R; Wiltfang J; Gruber O; Schüle C; Padberg F; Ising M; Uhr M; Friede T; Huber C; Manook A; Baghai TC; Rupprecht R; Heuser I
    JAMA Netw Open; 2022 Sep; 5(9):e2230367. PubMed ID: 36103181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.